http://rdf.ncbi.nlm.nih.gov/pubchem/patent/CA-2531486-A1

Outgoing Links

Predicate Object
assignee http://rdf.ncbi.nlm.nih.gov/pubchem/patentassignee/MD5_966a6c1f382ec9bcb5e3839dfd73e5b8
classificationCPCInventive http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61K9-28
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61P31-18
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61K31-551
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61K9-1635
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61K9-1652
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61K9-1623
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61K9-20
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61P43-00
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61K9-2027
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61K9-2018
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61K9-2054
classificationIPCInventive http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61K9-28
http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61K31-551
http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61K9-20
http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61K9-00
filingDate 2004-07-05-04:00^^<http://www.w3.org/2001/XMLSchema#date>
inventor http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_5945f6ec2200deb3ec52899bc97805b0
http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_f31656c8a45814bf5646196f9322d9dd
http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_21919fca0cb6b6112cc5407051b50768
http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_534683b566711b79535c693927381403
http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_79cec613c3c94c3d4376704736b26415
publicationDate 2005-01-20-04:00^^<http://www.w3.org/2001/XMLSchema#date>
publicationNumber CA-2531486-A1
titleOfInvention Saquinavir mesylate oral dosage form
abstract A solid unit oral pharmaceutical dosage form of saquinavir mesylate is provided comprising micronized saquinavir mesylate in an amount of from 250 mg to 800 mg calculated as free base, and a pharmaceutically acceptable binder, disintegrant, and water soluble carrier. A solid unit dosage form of saquinavir mesylate is provided comprising from 60% to 80% micronized saquinavir mesylate based on the mesylate salt, 4% to 8% water soluble binder, a disintegrant and a carrier, wherein each percentage is of the kernel weight.
priorityDate 2003-07-11-04:00^^<http://www.w3.org/2001/XMLSchema#date>
type http://data.epo.org/linked-data/def/patent/Publication

Incoming Links

Predicate Subject
isDiscussedBy http://rdf.ncbi.nlm.nih.gov/pubchem/compound/CID962
http://rdf.ncbi.nlm.nih.gov/pubchem/compound/CID11177
http://rdf.ncbi.nlm.nih.gov/pubchem/substance/SID419512635
http://rdf.ncbi.nlm.nih.gov/pubchem/substance/SID419474469
http://rdf.ncbi.nlm.nih.gov/pubchem/compound/CID62223
http://rdf.ncbi.nlm.nih.gov/pubchem/substance/SID453754419
http://rdf.ncbi.nlm.nih.gov/pubchem/compound/CID85257
http://rdf.ncbi.nlm.nih.gov/pubchem/substance/SID449454525
http://rdf.ncbi.nlm.nih.gov/pubchem/compound/CID6917
http://rdf.ncbi.nlm.nih.gov/pubchem/substance/SID419527835
http://rdf.ncbi.nlm.nih.gov/pubchem/substance/SID449764502
http://rdf.ncbi.nlm.nih.gov/pubchem/substance/SID419503904
http://rdf.ncbi.nlm.nih.gov/pubchem/compound/CID441243
http://rdf.ncbi.nlm.nih.gov/pubchem/compound/CID60934

Total number of triples: 42.